Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.’s FY2017 Earnings (ALDX)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for shares of Aldeyra Therapeutics in a report released on Wednesday. Cantor Fitzgerald analyst E. Piros anticipates that the biotechnology company will earn ($1.30) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $22.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2018 earnings at ($1.29) EPS.
A number of other analysts also recently commented on the company. Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reaffirmed an “outperform” rating and set a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Aldeyra Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $16.96.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02.
In other news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $1,450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in ALDX. Virtu KCG Holdings LLC purchased a new position in shares of Aldeyra Therapeutics in the second quarter valued at $104,000. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics in the first quarter valued at $132,000. Hikari Power Ltd grew its position in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 31.0% in the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares in the last quarter. 40.32% of the stock is owned by institutional investors and hedge funds.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.